EGFR and non-small cell lung carcinoma: Gefitinib, the first approved EGFR-TKI, is still widely used as first-line treatment agent in advanced NSCLC patients harboring EGFR mutations, especially exon 19 deletion and exon 20 L858R point mutation [25].